| Prev Close | 115.73 |
| Open | 115.54 |
| Day Low/High | 114.91 / 116.90 |
| 52 Wk Low/High | 94.15 / 119.05 |
| Volume | 524.61K |
| Avg Volume | 309.40K |
| Exchange | NYSE |
| Shares Outstanding | 47.91M |
| Market Cap | 5.60B |
| EPS | 2.60 |
| P/E Ratio | 44.12 |
| Div & Yield | N.A. (N.A) |
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2018 Global Healthcare Conference in New York, New York, on Wednesday, June 6 th, at 11:00 a.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRL, DXCM, EVTC, GEC, KRC, WRLD, WWW Downgrades: ACIW, DHT, MDP, PPC, SPKE, SUN, SYMC Initiations: AYX, CLPR, EGC Read on to get TheStreet Quant Ratings' detailed report:
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2018.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 5.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 39 th Annual Institutional Investors Conference in Orlando, Florida, on Tuesday, March 6 th, at 3:25 p.
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model Compendium web interface.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Charles River Laboratories International, Inc. (NYSE: CRL) today announced two new executive management appointments.
Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2017 and provided guidance for 2018.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca's (NYSE: AZN) high-throughput screening (HTS) and compound management...
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13 th, before the market opens.
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 36 th Annual J.
